Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Evaluation of Allied Healthcare in Patients Recovering From COVID-19 (ParaCOV)

9. Mai 2022 aktualisiert von: Radboud University Medical Center

SUMMARY Rationale: Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) might play an important role in the recovery of patients with COVID-19 who experience limitations in daily physical functioning and participation. However, the evidence base for allied healthcare in patients with COVID-19 has yet to be established. To facilitate care for people recovering from COVID-19 and to establish this evidence base, the Dutch ministry has created a temporary regulation for primary care allied healthcare specifically for patients with COVID-19.

Objective: This study is setup alongside the temporary regulation and aims to evaluate the longitudinal recovery trajectories and related costs of patients who visited a primary care allied healthcare professional for the management of severe symptoms and activity limitations and/or participation restrictions related to COVID-19.

Study design: Prospective cohort study. Study population: 1,315 adult patients recovering from COVID-19 with severe symptoms and activity limitations and/or participation restrictions, and who are referred to a primary care allied health professional by a general practitioner or medical specialist within four months of the start of the disease will be eligible for this study.

Intervention (if applicable): Although the nature of this study is non-experimental, the allied healthcare intervention can be considered experimental due to the novelty of the disease.

Main study parameters/endpoints: The primary outcome domain of this study is participation measured with the Utrechtse Schaal voor Revalidatie - Participatie (USER-P). The primary endpoint is set at 6 months. A 5 point difference will be considered clinically relevant for patients with COVID-19.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There are no specific risks involved with participation in this study, as it entails the completion of questionnaires over the timeframe of one year (at the start of the treatment, the end of the treatment, 3 months, 6 months, 9 months and 12 months). The load of the survey will be highest at months 3, 6 and 12 with a total of 74 survey items. Input from patient representatives suggested that this number of items was feasible, especially because participants are allowed to complete the survey over a number of days. Finally, none of the items in the survey are considered emotionally distressing. The prescribed interventions are conform the recommendations of the best available evidence and are in line with usual allied healthcare interventions. Therefore, risks are likely to be negligible conform usual allied healthcare.

Studienübersicht

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

1441

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Gelderland
      • Nijmegen, Gelderland, Niederlande, 6500HB
        • Radboud University Medical Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

N/A

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

Adult patients of 18 year and older recovering from COVID-19 with severe symptoms and activity limitations and/or participation restrictions, who are referred to a primary care allied health professional* by a general practitioner or medical specialist are deemed eligible for this study.

*Allied health professionals relevant to this study are: Dietitians, Exercise Therapists, Occupational Therapists, Physical Therapists, and Speech and Language Therapists working in primary care in the Netherlands.

Beschreibung

Inclusion Criteria:

Adult patients

  • recovering from COVID-19 with severe symptoms and activity limitations and/or participation restrictions, and;
  • who are referred to a primary care allied health professional by a general practitioner or medical specialist within four months of the start of the disease; will be eligible for this study. The need for referring the patient to an allied health professional will be judged by the primary care physician or medical specialist. Criteria for referral are described in guidance published by the Long Alliantie Nederland (LAN) with recommendations for treatment of post-COVID-19-patients: the COVID-19 Associated Syndrome (CAS) (Chapters 3.3 and 4).

http://www.longalliantie.nl/files/2515/9359/4621/Handreiking_voor_de_zorg.pdf

Exclusion Criteria:

Adult patients:

- receiving palliative care; are excluded from this study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Prospective cohort
Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that treat patients recovering from COVID-19 in Dutch primary care
We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
Retrospective cohort
Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that have been treated patients recovering from COVID-19 in Dutch primary care
We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Participation
Zeitfenster: Baseline (T0)
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
Baseline (T0)
Participation
Zeitfenster: 3 months (T1)
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
3 months (T1)
Participation
Zeitfenster: 6 months (T2)
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
6 months (T2)
Participation
Zeitfenster: 12 months (T3)
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
12 months (T3)
Quality of life measured with EQ-5D-5L
Zeitfenster: Baseline (T0)
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
Baseline (T0)
Quality of life measured with EQ-5D-5L
Zeitfenster: 3 months (T1)
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
3 months (T1)
Quality of life measured with EQ-5D-5L
Zeitfenster: 6 months (T2)
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
6 months (T2)
Quality of life measured with EQ-5D-5L
Zeitfenster: 12 months (T3)
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
12 months (T3)
Fatigue
Zeitfenster: Baseline (T0)
Measured with the Fatigue Severity Scale (FSS)
Baseline (T0)
Fatigue
Zeitfenster: 3 months (T1)
Measured with the Fatigue Severity Scale (FSS)
3 months (T1)
Fatigue
Zeitfenster: 6 months (T2)
Measured with the Fatigue Severity Scale (FSS)
6 months (T2)
Fatigue
Zeitfenster: 12 months (T3)
Measured with the Fatigue Severity Scale (FSS)
12 months (T3)
Physical functioning
Zeitfenster: Baseline (T0)
PROMIS Physical Functioning Short Form 10b (10 items).
Baseline (T0)
Physical functioning
Zeitfenster: 3 months (T1)
PROMIS Physical Functioning Short Form 10b (10 items).
3 months (T1)
Physical functioning
Zeitfenster: 6 months (T2)
PROMIS Physical Functioning Short Form 10b (10 items).
6 months (T2)
Physical functioning
Zeitfenster: 12 months (T3)
PROMIS Physical Functioning Short Form 10b (10 items).
12 months (T3)
Costs
Zeitfenster: Baseline (T0)
will be measured using a cost questionnaire (18 items)
Baseline (T0)
Costs
Zeitfenster: 3 months (T1)
will be measured using a cost questionnaire (18 items)
3 months (T1)
Costs
Zeitfenster: 6 months (T2)
will be measured using a cost questionnaire (18 items)
6 months (T2)
Costs
Zeitfenster: 9 months (T3)
will be measured using a cost questionnaire (18 items)
9 months (T3)
Costs
Zeitfenster: 12 months (T4)
will be measured using a cost questionnaire (18 items)
12 months (T4)
Patient Specific Activities
Zeitfenster: baseline (T0) as part of usual care
measured with the Patient Specific Complaints (PSC)
baseline (T0) as part of usual care
Patient Specific Activities
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
measured with the Patient Specific Complaints (PSC)
end of the treatment as part of usual care (average of 6 months)
Nutritional Status
Zeitfenster: baseline (T0) as part of usual care
measured with the BMI (weight and height)
baseline (T0) as part of usual care
Nutritional Status
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
measured with the BMI (weight and height)
end of the treatment as part of usual care (average of 6 months)
Global Assessment
Zeitfenster: baseline (T0) as part of usual care
measured with the PG-SGA short form weight history, food intake, symptoms, activities and function).
baseline (T0) as part of usual care
Global Assessment
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
measured with the PG-SGA short form weight history, food intake, symptoms, activities and function).
end of the treatment as part of usual care (average of 6 months)
Voice Problems
Zeitfenster: baseline (T0) as part of usual care
measured with Voice Handicap Index (VHI)
baseline (T0) as part of usual care
Voice Problems
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
measured with Voice Handicap Index (VHI)
end of the treatment as part of usual care (average of 6 months)
Swallowing Problems
Zeitfenster: baseline (T0) as part of usual care
Dysphagia Handicap Index (DHI).
baseline (T0) as part of usual care
Swallowing Problems
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
Dysphagia Handicap Index (DHI).
end of the treatment as part of usual care (average of 6 months)
Patient Specific Activities
Zeitfenster: baseline (T0) as part of usual care
measured with the Canadian Occupational Performance Measure (COPM)
baseline (T0) as part of usual care
Patient Specific Activities
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
measured with the Canadian Occupational Performance Measure (COPM)
end of the treatment as part of usual care (average of 6 months)
Activities
Zeitfenster: baseline (T0) as part of usual care
measured with the PRO-ergo
baseline (T0) as part of usual care
Activities
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
measured with the PRO-ergo
end of the treatment as part of usual care (average of 6 months)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Exercise capacity
Zeitfenster: baseline (T0) as part of usual care
6 Minute Walk Test (6MWT)
baseline (T0) as part of usual care
Exercise capacity
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
6 Minute Walk Test (6MWT)
end of the treatment as part of usual care (average of 6 months)
Exercise capacity
Zeitfenster: baseline (T0) as part of usual care
Short Physical Performance Battery (SPPB)
baseline (T0) as part of usual care
Exercise capacity
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
Short Physical Performance Battery (SPPB)
end of the treatment as part of usual care (average of 6 months)
Quadriceps strength
Zeitfenster: baseline (T0) as part of usual care
with a hand dynamometer.
baseline (T0) as part of usual care
Quadriceps strength
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
with a hand dynamometer.
end of the treatment as part of usual care (average of 6 months)
Hand grip strength
Zeitfenster: baseline (T0) as part of usual care
with a hand dynamometer.
baseline (T0) as part of usual care
Hand grip strength
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
with a hand dynamometer.
end of the treatment as part of usual care (average of 6 months)
Bioimpedance (BIA
Zeitfenster: baseline (T0) as part of usual care
baseline (T0) as part of usual care
Bioimpedance (BIA
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
end of the treatment as part of usual care (average of 6 months)
VAS-appetite, taste and smell
Zeitfenster: baseline (T0) as part of usual care
baseline (T0) as part of usual care
VAS-appetite, taste and smell
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
end of the treatment as part of usual care (average of 6 months)
Dietary goal attainment
Zeitfenster: baseline (T0) as part of usual care
baseline (T0) as part of usual care
Dietary goal attainment
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
end of the treatment as part of usual care (average of 6 months)
Liquid medical nutrition
Zeitfenster: baseline (T0) as part of usual care
baseline (T0) as part of usual care
Liquid medical nutrition
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
end of the treatment as part of usual care (average of 6 months)
Sarcopenia
Zeitfenster: baseline (T0) as part of usual care
measured with the SARC-F
baseline (T0) as part of usual care
Sarcopenia
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
measured with the SARC-F
end of the treatment as part of usual care (average of 6 months)
Types of Stool
Zeitfenster: baseline (T0) as part of usual care
measured with the Bristol Stool Chart (BCS)
baseline (T0) as part of usual care
Types of Stool
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
measured with the Bristol Stool Chart (BCS)
end of the treatment as part of usual care (average of 6 months)
Voice Problems
Zeitfenster: baseline (T0) as part of usual care
measured with Maximum Phonation Time (MPT)
baseline (T0) as part of usual care
Voice Problems
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
measured with Maximum Phonation Time (MPT)
end of the treatment as part of usual care (average of 6 months)
Swallowing Problems
Zeitfenster: baseline (T0) as part of usual care
measured with Maximum Swallowing Speed (MSP)
baseline (T0) as part of usual care
Swallowing Problems
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
measured with Maximum Swallowing Speed (MSP)
end of the treatment as part of usual care (average of 6 months)
Physical Functioning
Zeitfenster: baseline (T0) as part of usual care
measured with the Assessment of Motor and Process Skills (AMPS)
baseline (T0) as part of usual care
Physical Functioning
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
measured with the Assessment of Motor and Process Skills (AMPS)
end of the treatment as part of usual care (average of 6 months)
Cognitive Functioning
Zeitfenster: baseline (T0) as part of usual care
measured with the Cognitive Complaints - Participation (CoCo-P)
baseline (T0) as part of usual care
Cognitive Functioning
Zeitfenster: end of the treatment as part of usual care (average of 6 months)
measured with the Cognitive Complaints - Participation (CoCo-P)
end of the treatment as part of usual care (average of 6 months)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Philip van der Wees, Prof. dr., Radboud University Medical Center

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

29. März 2021

Primärer Abschluss (Voraussichtlich)

17. Juli 2022

Studienabschluss (Voraussichtlich)

1. Januar 2024

Studienanmeldedaten

Zuerst eingereicht

28. Januar 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. Februar 2021

Zuerst gepostet (Tatsächlich)

3. Februar 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

10. Mai 2022

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. Mai 2022

Zuletzt verifiziert

1. Mai 2022

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Covid19

Abonnieren